My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1542

    1.

    Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).

    Davis TM, Cull CA, Holman RR; U.K. Prospective Diabetes Study (UKPDS) Group.

    Diabetes Care. 2001 Jul;24(7):1167-74.PMID: 11423497 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The impact of outpatient diabetes management on serum lipids in urban African-Americans with type 2 diabetes.

    Erdman DM, Cook CB, Greenlund KJ, Giles WH, El-Kebbi I, Ryan GJ, Gallina DL, Ziemer DC, Dunbar VG, Phillips LS.

    Diabetes Care. 2002 Jan;25(1):9-15.PMID: 11772894 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.

    [No authors listed]

    Diabetes Care. 1998 Jan;21(1):87-92.PMID: 9538975 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

    Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

    Diabetes Care. 1998 May;21(5):701-5.PMID: 9589227 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    6.

    Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

    Turner RC, Cull CA, Frighi V, Holman RR.

    JAMA. 1999 Jun 2;281(21):2005-12.PMID: 10359389 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

    Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group.

    Diabetes Care. 2004 Jan;27(1):141-7.PMID: 14693980 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.

    Clin Ther. 2004 May;26(5):744-54.PMID: 15220018 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    10.

    United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.

    [No authors listed]

    Ann Intern Med. 1998 Feb 1;128(3):165-75.PMID: 9454524 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.

    Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS.

    Diabetes Care. 1995 Aug;18(8):1113-23.PMID: 7587846 [PubMed - indexed for MEDLINE]Related articles

    12.

    Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.

    Chow CC, Tsang LW, Sorensen JP, Cockram CS.

    Diabetes Care. 1995 Mar;18(3):307-14.PMID: 7555472 [PubMed - indexed for MEDLINE]Related articles

    13.

    U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.

    [No authors listed]

    Diabetes. 1995 Nov;44(11):1249-58. Erratum in: Diabetes 1996 Nov;45(11):1655. PMID: 7589820 [PubMed - indexed for MEDLINE]Related articles

    14.

    Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.

    Dailey GE 3rd, Mohideen P, Fiedorek FT.

    Clin Ther. 2002 Sep;24(9):1426-38.PMID: 12380634 [PubMed - indexed for MEDLINE]Related articles

    15.

    Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). UK Prospective Diabetes Study Group.

    Manley SE, Stratton IM, Cull CA, Frighi V, Eeley EA, Matthews DR, Holman RR, Turner RC, Neil HA; United Kingdom Prospective Diabets Study Group.

    Diabet Med. 2000 Jul;17(7):518-23.PMID: 10972581 [PubMed - indexed for MEDLINE]Related articles

    16.

    Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

    Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

    J Clin Pharm Ther. 2009 Feb;34(1):13-23.PMID: 19125899 [PubMed - indexed for MEDLINE]Related articles

    17.

    Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects.

    Ozata M, Gungor D, Turan M, Ozisik G, Bingol N, Ozgurtas T, Ozdemir IC.

    J Clin Endocrinol Metab. 2001 Aug;86(8):3659-64.PMID: 11502793 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    19.

    UK Prospective Diabetes Study (UKPDS). X. Urinary albumin excretion over 3 years in diet-treated type 2, (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia.

    [No authors listed]

    Diabetologia. 1993 Oct;36(10):1021-9.PMID: 8243850 [PubMed - indexed for MEDLINE]Related articles

    20.

    Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

    Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity